Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › melphalan

melphalan

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of melphalan

148 trials tracked of melphalan: 15 in phase 3 or 4 and 4 with published results. The most-cited published study has 354 citations.

148Trials tracked
15Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 1 Phase 3 14 Phase 2 118 Phase 1 5 Other / NA 10
  1. Phase 3 Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma Completed · 354 cited
  2. Phase 3 A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma Completed · 140 cited
  3. Phase 3 Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma Completed · 129 cited
  4. Phase 3 A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma Completed · 102 cited
  5. Phase 4 Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Completed
  6. Phase 3 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Completed
Show 44 more trials
  1. Phase 3 Autologous Transplant for Multiple Myeloma Completed
  2. Phase 3 Stem Cell Transplantation for Sickle Cell Anemia Completed
  3. Phase 3 A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. Completed
  4. Phase 3 Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone Completed
  5. Phase 3 Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma Completed
  6. Phase 3 DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation Completed
  7. Phase 3 UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy Completed
  8. Phase 3 Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis Completed
  9. Phase 3 Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis Completed
  10. Phase 2 Stem Cell Transplant for Immunologic or Histiocytic Disorders Completed
  11. Phase 2 HSCT for High Risk Inherited Inborn Errors Completed
  12. Phase 2 Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Completed
  13. Phase 2 Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma Completed
  14. Phase 2 Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma Completed
  15. Phase 2 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed
  16. Phase 2 Off-the-shelf NK Cells + SCT for Myeloid Malignancies Completed
  17. Phase 2 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer Completed
  18. Phase 2 Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma Completed
  19. Phase 2 Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia Completed
  20. Phase 2 Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma Completed
  21. Phase 2 Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies Completed
  22. Phase 2 Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma Completed
  23. Phase 2 Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer Completed
  24. Phase 2 Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis Completed
  25. Phase 2 Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma Completed
  26. Phase 2 Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Completed
  27. Phase 2 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  28. Phase 2 Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed
  29. Phase 2 S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis Completed
  30. Phase 2 Autologous Transplant in HIV Patients (BMT CTN 0803) Completed
  31. Phase 2 Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas Completed
  32. Phase 2 Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma Completed
  33. Phase 2 Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies Completed
  34. Phase 2 Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma Completed
  35. Phase 2 S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma Completed
  36. Phase 2 Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease Completed
  37. Phase 2 Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR Completed
  38. Phase 2 Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant Completed
  39. Phase 2 Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma Completed
  40. Phase 2 Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG Completed
  41. Phase 2 High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease Completed
  42. Phase 2 Reduced Intensity Conditioning Transplant Using Haploidentical Donors Completed
  43. Phase 2 N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma Completed
  44. Phase 2 Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma Completed

Showing the 50 most-cited and recently-updated of 148 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
UK trial reports 4-year event-free survival of 63% and overall survival of 68% in relapsed Wilms tumour patients
Pediatrics
UK trial reports 4-year event-free survival of 63% and overall survival of 68% in relapsed Wilms tumour patients High-dose chemo plus stem cell rescue offers hope for relapsed Wilms tumour
This clinical trial report evaluates outcomes for 78 children with relapsed or refractory Wilms tumour treated in the United Kingdom.
A UK trial found that a risk-stratified protocol with high-dose melphalan and stem cell rescue helped some children with relapsed Wilms tumo…
May 1, 2026
Autologous hematopoietic stem cell transplantation improves disease-free survival in pediatric extraocular retinoblastoma patients
Pediatrics Cohort
Autologous hematopoietic stem cell transplantation improves disease-free survival in pediatric extraocular retinoblastoma patients Children With Eye Cancer Now Have a New Hope for Survival
This retrospective analysis included 12 children with extraocular retinoblastoma treated with autologous hematopoietic stem cell transplanta…
Children with advanced eye cancer can now achieve long-term survival using their own stem cells, especially if the disease has not reached t…
Frontiers Apr 29, 2026
Itacitinib plus standard therapy in acute leukemia or myelofibrosis patients undergoing reduced-intensity conditioning donor stem cell transplantation
Oncology Phase II
Itacitinib plus standard therapy in acute leukemia or myelofibrosis patients undergoing reduced-intensity conditioning donor stem cell transplantation Early trial explores itacitinib for stem cell transplant patients with blood disorders
This Phase IIa trial evaluated itacitinib combined with tacrolimus and sirolimus in patients with acute leukemia, myelodysplastic syndrome, …
A new trial adds itacitinib to standard care for stem cell transplant patients with blood disorders to help prevent graft-versus-host diseas…
CT.gov Apr 13, 2026
Early daratumumab or immunomodulatory agents in high-risk smoldering multiple myeloma show uncertain benefits versus observation
Allergy & Immunology Sys. Review
Early daratumumab or immunomodulatory agents in high-risk smoldering multiple myeloma show uncertain benefits versus observation Early Drug May Delay Multiple Myeloma
This systematic review evaluated early intervention with monoclonal antibodies, immunomodulatory agents, or alkylating agents versus observa…
Imagine waking up with a headache. You take a pill, and the pain goes away.
Cochrane Apr 10, 2026
SVRD yields 89.7% ORR, 79.3% EMD resolution in NDMM with EMD in phase 2 trial
Oncology Phase II
SVRD yields 89.7% ORR, 79.3% EMD resolution in NDMM with EMD in phase 2 trial Can a new drug combination help people with aggressive multiple myeloma? Early results show promise
In a phase 2 trial of 29 patients with newly diagnosed multiple myeloma and extramedullary disease (EMD), selinexor combined with VRD (SVRD)…
A new four-drug combination helped nearly 90% of patients with aggressive multiple myeloma shrink or eliminate cancer outside the bone marro…
Mar 30, 2026